TH News and Press, Target Hospitality Corp. From 09/29/23

Arrow Bidco, LLC Announces Exchange Offer and Consent Solicitation in respect of its Senior Secured Notes PR Newswire THE WOODLANDS, Texas , Sept. 29, 2023 /PRNewswire/ -- Arrow Bidco, LLC (the "Issuer"), a Delaware limited liability company and an indir...

Q3 2023 consolidated revenue of $20.9 million, adjusted EBITDA of $2.2 million sBLA for F8 formulation of tesamorelin submitted to FDA Agreement in principle on key amendments to loan facility with Marathon MONTREAL, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (&...

- Removal of Minimum Liquidity Covenant of US$30 Million if F8 Formulation of Tesamorelin is Not Approved by the FDA by March 31, 2024 - Minimum Liquidity Covenant to Decrease Over Time to a Minimum of US$15 million from US$20 Million Based on Attainment of Targeted Adjusted EBITDA ...

F8 formulation intended to replace EGRIFTA SV ® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy MONTREAL, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Co...

2023-09-22 12:28:31 ET Summary Target Hospitality is a modular housing community company serving the energy industry and US government, with a majority of revenue and profitability coming from government contracts. The company operates 27 communities with almost 17,000 available b...

MONTREAL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Paul L&#x...

MONTREAL, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will r...

MONTREAL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Lév...

- 2023 Q3 positive adjusted EBITDA to be achieved - Cash, bonds and money market funds of US$22.9 million as at August 31, 2023 This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 1...

MONTREAL, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of th...